<DOC>
	<DOCNO>NCT00837863</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness ALTU-238 treatment child growth hormone deficiency yet reach puberty lack normal ability make growth hormone . This study also test ALTU-238 work weekly treatment .</brief_summary>
	<brief_title>Study Weekly ALTU-238 Compared With Daily Nutropin AQ Prepubertal Children With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 . Assent subject , applicable , write informed consent parent legal guardian 2 . Diagnosis GHD define maximum stimulated GH &lt; 7 ng/mL ( μg/L ) two stimulation test ( use two distinct agent follow list : arginine , Ldopa , clonidine , insulin , glucagon ) ; two document historical test available , test ( ) must perform Screening period 3 . Available result one historical CT MRI scan head obtain follow diagnosis GHD 4 . Chronologic age Screening 3 13 year ( inclusive ) boys 3 12 year ( inclusive ) girl 5 . Bone age Screening ≤ 11 year boys ≤ 10 year girls 6 . Prepubertal Screening ( Tanner stage 1 breast/genitalia pubic hair 7 . For subject idiopathic GHD , Screening height SDS ≤ 2.0 ( standardize chronologic age sex ) height SDS requirement subject organic GHD ( define CNS lesion insult historical CT MRI scan ) 8 . Pretreatment annualized height velocity ≤ median ( 50th percentile ) chronologic age sex ( base value delay maturers provide Appendix 4 ) , utilize Screening height height obtain 52 ± 13 week ( i.e . 39 65 week ) prior Screening 9 . Screening IGF1 SDS chronologic age sex &lt; 1 10 . If thyroid hormone replacement therapy , dose must stable least 6 week prior Screening free thyroxine level ( T4 ) , TSH , cortisol must within normal range Screening visit 1 . History prior rhGH , rhIGF1 , sex steroid treatment 2 . History treatment medication may affect growth 3 . Evidence active intracranial neoplasm per recent serial CT MRI scan head criterion 4 . Surgery/chemotherapy/radiation therapy intracranial neoplasm within prior 52 week 5 . Any history nonintracranial neoplasm 6 . History active benign intracranial hypertension 7 . Highdose chronic systemic corticosteroid treatment ( oral inject ) within prior 13 week 8 . Acute severe illness within prior 26 week 9 . History diabetes mellitus , anorexia nervosa , cystic fibrosis , chronic severe kidney liver disease , chronic infectious disease , inborn error metabolism , chromosomal disorder , intrauterine growth retardation , childhood disease associate growth failure 10 . History congenital syndromes associate abnormal growth , include Turner syndrome , Noonan syndrome , PraderWilli syndrome , etc . 11 . History severe associate pathology affect growth , include malnutrition , malabsorption , bone dysplasia 12 . History autoimmune disease 13 . Serum ALT AST ≥ 1.5X ULN 14 . Participation another clinical trial treatment investigational agent ( drug biologic ) within 30 day prior Baseline halflife agent know ≤ 6 day within 6 week prior Baseline halflife &gt; 6 day know 15 . History allergic abnormal reaction component study drug 16 . Any previous ongoing clinically significant illness , PE finding , laboratory abnormality , opinion Investigator Medical Monitor , could prevent subject complete protocolspecified requirement successfully 17 . Poor likelihood , Investigator 's opinion , subject comply protocol requirement ( e.g. , uncooperative attitude , inability return followup visit , history medical noncompliance ) and/or poor likelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>